Differences in allelic distribution of two polymorphisms in the VHL-associated gene CUL2 in pheochromocytoma patients without somatic CUL2 mutations

Journal of Clinical Endocrinology and Metabolism

Volumn 84, Issue 9, 1999, Pages 3207-3211

  Duerr, Eva Maria ^a,b,c   Gimm, Oliver ^a   Neuberg, Donna S ^b   Kum, Jennifer B ^a,b   Clifford, Steven C ^d   Toledo, Sergio P A ^e   Maher, Eamonn R ^d   Dahia, Patricia L M ^a,b,g   Eng, Charis ^a,f  

^a OHIO STATE UNIVERSITY   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF BONN   (Germany)

^d UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

^e UNIVERSITY OF SÃO PAULO   (Brazil)

^f UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^g DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ALLELE; ARTICLE; CLINICAL ARTICLE; FEMALE; GENE DELETION; GENETIC POLYMORPHISM; HUMAN; HUMAN CELL; INTRON; MALE; PATHOGENESIS; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; SCHOOL CHILD; SIPPLE SYNDROME; SOMATIC MUTATION; VON HIPPEL LINDAU DISEASE;

EID: 0033305321     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.84.9.3207     Document Type: Article

References (33)

1. Pheochromocytoma: Diagnosis, localization and management
2. Bilateral pheochromocytomas
3. Familial pheochromocytoma
4. Germline mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A
5. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC
6. Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours
7. Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B
8. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma
9. Von Hippel-Lindau disease
10. Identification of intragenic mutations in the Von Hippel-Lindau disease tumour suppressor gene and correlation with disease phenotype
11. Germline mutations in the Von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan
12. Mutations in the RET proto-oncogene and the von Hippel-Lindau disease tumour suppressor gene in sporadic and syndromic phaeochromocytomas
13. Extensive mutation scanning of RET in sporadic medullary thyroid carcinoma and of RET and VHL in sporadic pheochromocytoma reveals involvement of these genes in only a minority of cases
14. Mutations in the RET protooncogene in sporadic pheochromocytomas
15. Molecular and immunohistochemical analysis of P53 in phaeochromocytoma
16. Deletion analysis of the p16 tumour suppressor gene in phaeochromocytomas
17. Mutation analysis of glial cell line-derived neurotrophic factor (GDNF), a ligand for the RET/GDNF receptor alpha complex, in sporadic phaeochromocytomas
18. Functions of the von Hippel-Lindau tumour suppressor protein
19. Inhibition of transcription elongation by the VHL tumor suppressor protein
20. Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C
21. Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongins B/C and Cul2
22. The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins
23. Genomic organisation and chromosomal localisation of the human CUL2 gene and the role of von Hippel-Lindau tumour suppressor-binding protein (CUL2 and VBP-1) mutation and loss in renal cell carcinoma development
24. Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors
25. PTEN is inversely correlated with the cell survival factor Akt/PKB and is inactivated via multiple mechanismsin haematological malignancies
26. Alterations in DNA methylation: A fundamental aspect of neoplasia
27. Over-representation of a germline RET sequence variant in patients with sporadic medullary thyroid carcinoma and somatic RET codon 918 mutation
28. Specific polymorphisms in the RET proto-oncogene are over-represented in individuals with Hirschsprung disease and may represent loci modifying phenotypic expression
29. Role of a p53 polymorphism in the development of human papillomavirus- associated cancer
30. Familial colorectal cancer in Ashkenazim due to a hypermutable tract in APC
31. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene
32. p53 codon 72 polymorphism and risk of cervical cancer in UK
33. No evidence of correlation between polymorphism at codon 72 of p53 and risk of cervical cancer in Japanese patients with human papillomavirus 16/18 infection